etanercept + salazosulfapyridine

Etanercept + salazosulfapyridine is a combination therapy used primarily in the management of rheumatoid arthritis, especially in patients who are intolerant to methotrexate. Etanercept is a biologic agent that acts as a tumor necrosis factor (TNF) inhibitor, blocking the activity of TNF-alpha, a cytokine involved in systemic inflammation. Salazosulfapyridine (also known as sulfasalazine) is a conventional disease-modifying antirheumatic drug (DMARD) with anti-inflammatory and immunomodulatory properties; it works by inhibiting various inflammatory mediators and modulating immune responses. The combination aims to enhance therapeutic efficacy for rheumatoid arthritis while providing an alternative for patients unable to tolerate methotrexate[1][4]. Clinical studies suggest this combination can be effective and well-tolerated in such populations[1][4].

Other names

etanercept + sulfasalazine